Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2023 WS
-
2021 SS
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 3
- begl. Vorlesung: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 2
- Klinische Nuklearmedizin: Grundlagen und Indikationen
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 1
- Der nuklearmedizinische Fall der Woche: Bildbeispiele, Indikationen und Grundlagen
- Anleitung zu selbständigen wissenschaftlichen Arbeiten in der Nuklearmedizin
- PJ - Seminar
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 2
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 880 - 887Online Volltext: dx.doi.org/
-
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyIn: European Urology Oncology Jg. 7 (2024) Nr. 5, S. 1132 - 1140Online Volltext: dx.doi.org/
-
Beyond Prostate Imaging Reporting and Data System : Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate CancerIn: The Journal of Urology Jg. 212 (2024) Nr. 2, S. 299 - 307Online Volltext: dx.doi.org/
-
Biodistribution and radiation dosimetry of ¹²⁴I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric modelsIn: EJNMMI Physics Jg. 11 (2024) Nr. 1, 3Online Volltext: dx.doi.org/ (Open Access)
-
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRTIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 51 (2024) Nr. 3, S. 841 - 851Online Volltext: dx.doi.org/ (Open Access)
-
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer : A multicentre retrospective studyIn: The Lancet Oncology Jg. 25 (2024) Nr. 9, S. 1188 - 1201Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to “Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management : Results from a Prospective Multicenter Randomized Phase 3 TrialIn: European Urology (2024) in pressOnline Volltext: dx.doi.org/
-
Delayed ⁶⁸Ga-FAPI-46 PET/MR imaging confirms ongoing fibroblast activation in patients after acute myocardial infarctionIn: International Journal of Cardiology (IJC) Heart & Vasculature Jg. 50 (2024) 101340Online Volltext: dx.doi.org/ (Open Access)
-
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [⁶⁸Ga]Ga-/[¹⁸F]F-PSMA-11/-1007, [⁶⁸Ga]Ga-FAPI-46 and 2-[¹⁸F]FDG PET/CT : a pilot studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 52 (2024) Nr. 1, S. 342 - 353Online Volltext: dx.doi.org/ (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-FAPI Versus ¹⁸F-FDG PET in Patients with Various MalignanciesIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 3, S. 372 - 378Online Volltext: dx.doi.org/ (Open Access)
-
Differences and Common Ground in ¹⁷⁷Lu-PSMA Radioligand Therapy Practice Patterns : International Survey of 95 Theranostic CentersIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 3, S. 438 - 445Online Volltext: dx.doi.org/ (Open Access)
-
Dose-Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1175 - 1180Online Volltext: dx.doi.org/
-
FAPI PET Imaging Supports Clinical Decision Making in Academic Cardiology Practice : A Pictorial Imaging VignetteIn: JACC Cardiovascular Imaging Jg. 17 (2024) Nr. 7, S. 811 - 823Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 2, S. 252 - 257Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1188 - 1193Online Volltext: dx.doi.org/
-
Head-to-head comparison of ⁶⁸ Ga-FAPI-46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsIn: Annals of Nuclear Medicine (2024) in pressOnline Volltext: dx.doi.org/
-
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)In: European Urology Jg. 86 (2024) Nr. 1, S. 52 - 60Online Volltext: dx.doi.org/
-
Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [⁶⁸Ga]-DOTATOC PET/MRIIn: Clinical and Translational Imaging Jg. 12 (2024) Nr. 4, S. 441 - 448Online Volltext: dx.doi.org/
-
Impact of ¹⁸F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer : Results from a Prospective Double-Center TrialIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 12, S. 1855 - 1861Online Volltext: dx.doi.org/
-
Implementation of PET/CT in radiation oncology : A patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation OncologyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 200 (2024) Nr. 11, S. 931 - 941Online Volltext: dx.doi.org/ (Open Access)
-
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary CancersIn: European Urology (2024) in pressOnline Volltext: dx.doi.org/
-
PSMA-PET follow-up to assess response in patients not receiving PSMA therapy : Is there value beyond localization of disease?In: Theranostics Jg. 14 (2024) Nr. 9, S. 3623 - 3633Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-PET research: addressing challenges and prospects : Authors' replyIn: The Lancet Oncology Jg. 25 (2024) Nr. 11, e533Online Volltext: dx.doi.org/
-
Prognostic Implications of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid TumorsIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 7, S. 1027 - 1034Online Volltext: dx.doi.org/
-
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer : An International Multicenter Retrospective StudyIn: European Urology Jg. 85 (2024) Nr. 6, S. 511 - 516Online Volltext: dx.doi.org/ (Open Access)
-
RECIP 1.0 Predicts Progression-Free Survival After [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 917 - 922Online Volltext: dx.doi.org/
-
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)In: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 7, S. 1076 - 1079Online Volltext: dx.doi.org/
-
Recurrent prostate cancer : combined role for MRI and PSMA-PET in ⁶⁸Ga-PSMA-11 PET/MRIIn: European Radiology Jg. 34 (2024) Nr. 7, S. 4789 - 4800Online Volltext: dx.doi.org/ (Open Access)
-
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World DatabaseIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 1, S. 94 - 99Online Volltext: dx.doi.org/ (Open Access)
-
Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA : A German Multicenter StudyIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 909 - 916Online Volltext: dx.doi.org/
-
Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine TumorsIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 931 - 937Online Volltext: dx.doi.org/
-
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison of Tissue, ⁶⁸Ga-FAPI-46 PET Data, and Survival DataIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1217 - 1223Online Volltext: dx.doi.org/
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics Jg. 14 (2024) Nr. 14, S. 5400 - 5412Online Volltext: dx.doi.org/ (Open Access)
-
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? : Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging ParametersIn: European Urology Oncology Jg. 7 (2024) Nr. 2, S. 231 - 240Online Volltext: dx.doi.org/
-
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy : a retrospective multi-institutional propensity score analysisIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 51 (2024) Nr. 12, S. 3770 - 3781Online Volltext: dx.doi.org/ (Open Access)
-
[⁶⁸Ga]Ga-FAPI versus 2-[¹⁸F]FDG PET/CT in patients with autoimmune thyroiditis : A case control studyIn: EJNMMI Research Jg. 14 (2024) Nr. 1, 66Online Volltext: dx.doi.org/ (Open Access)
-
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study)In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 12, S. 1925 - 1931Online Volltext: dx.doi.org/ (Open Access)
-
18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in MenIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 4, S. 598 - 604Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment : An International Multicenter Prospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 7, S. 1043 - 1048Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-Labeled Fibroblast Activation Protein Inhibitor (⁶⁸Ga-FAPI) PET for Pancreatic Adenocarcinoma : Data from the ⁶⁸Ga-FAPI PET Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 12, S. 1910 - 1917Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 10, S. 1540 - 1549Online Volltext: dx.doi.org/ (Open Access)
-
A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer PatientsIn: Cancers Jg. 15 (2023) Nr. 8, 2208Online Volltext: dx.doi.org/ (Open Access)
-
A VISION Substudy of Reader Agreement on ⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for ¹⁷⁷Lu-PSMA-617 Radioligand TherapyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 8, S. 1259 - 1265Online Volltext: dx.doi.org/ (Open Access)
-
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapyIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 10, e007354Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer Jg. 4 (2023) Nr. 9, S. 1395Online Volltext: dx.doi.org/ (Open Access)
-
Bone Metastases in Patients with Pancreatic NETs : Prevalence and PrognosisIn: Hormone and Metabolic Research Jg. 28 (2023) Nr. 4,Online Volltext: dx.doi.org/
-
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on ¹⁸F-FDG PET/MRI and Machine LearningIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 2, S. 304 - 311Online Volltext: dx.doi.org/ (Open Access)
-
Conventional Imaging, MRI and ¹⁸F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast CancerIn: Cancers Jg. 15 (2023) Nr. 14, 3646Online Volltext: dx.doi.org/ (Open Access)
-
Correction: Fully Automated, High-Dose Radiosynthesis of [18F]PARPiIn: Pharmaceuticals Jg. 16 (2023) Nr. 7, 1024Online Volltext: dx.doi.org/ (Open Access)
-
Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRIIn: Nuclear Medicine Communications Jg. 44 (2023) Nr. 12, S. 1106 - 1113Online Volltext: dx.doi.org/
-
DGN-Handlungsempfehlung (S1-Leitlinie) : PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms - Stand: 01/2022 - AWMF-Registernummer: 031-055In: Nuklearmedizin = Nuclear Medicine Jg. 62 (2023) Nr. 1, S. 5 - 19Online Volltext: dx.doi.org/
-
Demonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In VivoIn: Pharmaceuticals Jg. 16 (2023) Nr. 6, 824Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 6, S. 869 - 872Online Volltext: dx.doi.org/ (Open Access)
-
Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? : An International Multicenter Retrospective Study with Masked Independent ReadersIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 11, S. 1744 - 1747Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and Safety of¹²⁴I-MIBG Dosimetry-Guided High-Activity¹³¹I-MIBG Therapy of Advanced Pheochromocytoma or NeuroblastomaIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 6, S. 885 - 891Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of [⁶⁸Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital SpaceIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 8, S. 1185 - 1190Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of thresholding methods for the quantification of [⁶⁸Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 7, S. 2196 - 2209Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : The Case for Use in SarcomaIn: PET Clinics Jg. 18 (2023) Nr. 3, S. 361 - 367Online Volltext: dx.doi.org/
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 711 - 716Online Volltext: dx.doi.org/ (Open Access)
-
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel ToolIn: European Urology Oncology Jg. 6 (2023) Nr. 6, S. 543 - 552Online Volltext: dx.doi.org/
-
Incidental Detection of a Tenosynovial Giant Cell Tumor of the Thigh on [⁶⁸Ga]Ga-FAPI PET/CT : Presentation of an Unusual CaseIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 7, S. 1162 - 1163Online Volltext: dx.doi.org/
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer Jg. 4 (2023) Nr. 9, S. 1292 - 1308Online Volltext: dx.doi.org/ (Open Access)
-
Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy SpecimensIn: European Urology Open Science Jg. 54 (2023) S. 28 - 32Online Volltext: dx.doi.org/ (Open Access)
-
Is There a Role of Artificial Intelligence in Preclinical Imaging?In: Seminars in Nuclear Medicine Jg. 53 (2023) Nr. 5, S. 687 - 693Online Volltext: dx.doi.org/
-
Is ¹⁸F-FDG PET Needed to Assess ¹⁷⁷Lu-PSMA Therapy Eligibility? : A VISION-like, Single-Center AnalysisIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 731 - 737Online Volltext: dx.doi.org/ (Open Access)
-
Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT)In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 9, S. 2830 - 2845Online Volltext: dx.doi.org/ (Open Access)
-
Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide TherapyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 2, S. 329 - 336Online Volltext: dx.doi.org/ (Open Access)
-
Molecular Imaging of Lymphoma : Future Directions and PerspectivesIn: Seminars in Nuclear Medicine Jg. 53 (2023) Nr. 3, S. 449 - 456Online Volltext: dx.doi.org/
-
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid CarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 12, S. 1865 - 1868Online Volltext: dx.doi.org/ (Open Access)
-
Novel ⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related PitfallsIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 3, S. 368 - 371Online Volltext: dx.doi.org/ (Open Access)
-
Oncologic Staging with ⁶⁸Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than ¹⁸F-FDG PET/CTIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 12, S. 1906 - 1909Online Volltext: dx.doi.org/ (Open Access)
-
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy : An International Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 7, S. 1024 - 1029Online Volltext: dx.doi.org/ (Open Access)
-
PSMA PET/CT : Joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 5, S. 1466 - 1486Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 3, S. 372 - 378Online Volltext: dx.doi.org/ (Open Access)
-
Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancerIn: Endocrine Connections Jg. 12 (2023) Nr. 2, e220312Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Presurgical ⁶⁸Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment : A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging TrialIn: European Urology Jg. 84 (2023) Nr. 6, S. 588 - 596Online Volltext: dx.doi.org/
-
Prostate-specific Membrane Antigen Reporting and Data System Version 2.0In: European Urology Jg. 84 (2023) Nr. 5, S. 491 - 502Online Volltext: dx.doi.org/ (Open Access)
-
Quantification performance of silicon photomultiplier-based PET for small ¹⁸F-, ⁶⁸Ga- and ¹²⁴I-avid lesions in the context of radionuclide therapy planningIn: Physica Medica: European Journal of Medical Physics Jg. 114 (2023) 103149Online Volltext: dx.doi.org/ (Open Access)
-
Rabbit fever : granulomatous inflammation by Francisella tularensis mimics lung cancer in dual tracer ¹⁸FDG and ⁶⁸Ga-FAPI PET/CTIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 8, S. 2567 - 2569Online Volltext: dx.doi.org/ (Open Access)
-
Radioiodine Ablation of Thyroid Remnants in Patients with Graves' OrbitopathyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 4, S. 561 - 566Online Volltext: dx.doi.org/ (Open Access)
-
Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision : A phantom studyIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 67 (2023) Nr. 1, S. 57 - 68Online Volltext: dx.doi.org/
-
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerIn: Radiology Jg. 308 (2023) Nr. 1, e222148Online Volltext: dx.doi.org/
-
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET : Imaging Neuroendocrine TumorsIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 2, S. 204 - 210Online Volltext: dx.doi.org/ (Open Access)
-
SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 8, S. 1191 - 1194Online Volltext: dx.doi.org/ (Open Access)
-
Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment : The RALU StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 4, S. 574 - 578Online Volltext: dx.doi.org/ (Open Access)
-
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective studyIn: Radiotherapy and Oncology (The Green Journal) Jg. 184 (2023) 109678Online Volltext: dx.doi.org/
-
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)In: European Urology Jg. 83 (2023) Nr. 5, S. 405 - 412Online Volltext: dx.doi.org/ (Open Access)
-
Standardized PSMA-PET Imaging of Advanced Prostate CancerIn: Seminars in Nuclear Medicine Jg. 54 (2023) Nr. 1, S. 60 - 68Online Volltext: dx.doi.org/
-
Superior Tumor Detection for ⁶⁸Ga-FAPI-46 Versus ¹⁸F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 7, S. 1049 - 1055Online Volltext: dx.doi.org/ (Open Access)
-
Unspecific ¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 738 - 743Online Volltext: dx.doi.org/ (Open Access)
-
Using PSMA imaging for prognostication in localized and advanced prostate cancerIn: Nature Reviews Urology Jg. 20 (2023) Nr. 1, S. 23 - 47Online Volltext: dx.doi.org/
-
Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 7, S. 1102 - 1108Online Volltext: dx.doi.org/ (Open Access)
-
What Role Does PET/MRI Play in Musculoskeletal Disorders?In: Seminars in Nuclear Medicine (2023) in pressOnline Volltext: dx.doi.org/
-
[¹⁸F]FDG PET/MRI in children suffering from lymphoma : does MRI contrast media make a difference?In: European Radiology Jg. 33 (2023) Nr. 11, S. 8366 - 8375Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-FAPI as a Diagnostic Tool in Sarcoma : Data from the 68Ga-FAPI PET Prospective Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 1, S. 89 - 95Online Volltext: dx.doi.org/ (Open Access)
-
A Role for PET/CT in response assessment of malignant pleural mesotheliomaIn: Seminars in Nuclear Medicine Jg. 52 (2022) Nr. 6, S. 816 - 823Online Volltext: dx.doi.org/
-
A Role of PET/MR in Breast Cancer?In: Seminars in Nuclear Medicine Jg. 52 (2022) Nr. 5, S. 611 - 618Online Volltext: dx.doi.org/
-
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in MiceIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 9, S. 1357 - 1363Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Comparison of nodal staging between CT, MRI, and [¹⁸F]-FDG PET/MRI in patients with newly diagnosed breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) S. 992 - 1001Online Volltext: dx.doi.org/ (Open Access)
-
Correction to : Value of PET imaging for radiation therapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. 1, S. 80 - 82Online Volltext: dx.doi.org/ (Open Access)
-
Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with PheochromocytomaIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 6, S. 869 - 874Online Volltext: dx.doi.org/ (Open Access)
-
Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis : A Prospective Proof-of-Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and SpineIn: Arthritis & Rheumatology Jg. 74 (2022) Nr. 9, S. 1497 - 1505Online Volltext: dx.doi.org/ (Open Access)
-
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI) : A Single-Center Prospective Two-Arm StudyIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4194 - 4202Online Volltext: dx.doi.org/ (Open Access)
-
FDG-PET Positivity and Overall Survival in Renal Cell CarcinomaIn: JAMA Network Open Jg. 5 (2022) Nr. 11, e2242289Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
First experiences with dynamic renal [⁶⁸Ga]Ga-DOTA PET/CT : A comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rateIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. 10, S. 3373 - 3386Online Volltext: dx.doi.org/ (Open Access)
-
Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRIIn: EJNMMI Physics Jg. 9 (2022) Nr. 1, 11Online Volltext: dx.doi.org/ (Open Access)
-
Fully Automated, High-Dose Radiosynthesis of [18F]PARPiIn: Pharmaceuticals Jg. 15 (2022) Nr. 7, 865Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Improved production of ⁶⁸Ga-Pentixafor using cartridge mediated cation exchange purificationIn: Applied Radiation and Isotopes Jg. 189 (2022) 110447Online Volltext: dx.doi.org/
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 727 - 734Online Volltext: dx.doi.org/ (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia Jg. 36 (2022) Nr. 12, S. 2845 - 2852Online Volltext: dx.doi.org/ (Open Access)
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. 12, S. 4271 - 4281Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After ProstatectomyIn: International Journal of Radiation Oncology, Biology, Physics Jg. 113 (2022) Nr. 5, S. 1015 - 1024Online Volltext: dx.doi.org/
-
Multiparametric¹⁸F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast CancerIn: Cancers Jg. 14 (2022) Nr. 7, 1727Online Volltext: dx.doi.org/ (Open Access)
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 11, S. 1651 - 1658Online Volltext: dx.doi.org/ (Open Access)
-
Onkologische Theranostik in der NuklearmedizinIn: Die Radiologie Jg. 62 (2022) Nr. 10, S. 875 - 884Online Volltext: dx.doi.org/
-
Onkologische Theranostik in der NuklearmedizinIn: Die Onkologie Jg. 28 (2022) Nr. 7, S. 612 - 622Online Volltext: dx.doi.org/
-
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 1, S. 76 - 80Online Volltext: dx.doi.org/ (Open Access)
-
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients : A Multicenter Retrospective StudyIn: Cancers Jg. 14 (2022) Nr. 22, 5680Online Volltext: dx.doi.org/ (Open Access)
-
Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital systemIn: BMC Cancer Jg. 22 (2022) Nr. 1, 899Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET : A Pictorial AnalysisIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 6, S. 890 - 896Online Volltext: dx.doi.org/ (Open Access)
-
Prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) für Urologen : Wann und welcher Tracer?In: Der Urologe Jg. 61 (2022) Nr. 4, S. 384 - 391Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer : A Retrospective Single-center StudyIn: European Urology Oncology Jg. 5 (2022) Nr. 5, S. 544 - 552Online Volltext: dx.doi.org/
-
Radiation Protection and Occupational Exposure on ⁶⁸Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted ProstatectomyIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 9, S. 1349 - 1356Online Volltext: dx.doi.org/ (Open Access)
-
Repeatability of ⁶⁸Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor VolumeIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 746 - 753Online Volltext: dx.doi.org/ (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 3, S. 396 - 398Online Volltext: dx.doi.org/ (Open Access)
-
Response to letter to the editorIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. 10, S. 3336 - 3339Online Volltext: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4346 - 4353Online Volltext: dx.doi.org/ (Open Access)
-
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET : Myth or Reality?In: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 2, S. 226 - 232Online Volltext: dx.doi.org/ (Open Access)
-
¹⁸F-PSMA-11 Versus ⁶⁸Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer : A Prospective Double-blind Randomised Cross-over TrialIn: European Urology Jg. 82 (2022) Nr. 5, S. 501 - 509Online Volltext: dx.doi.org/
-
⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomasIn: Scientific Reports Jg. 12 (2022) Nr. 1, 16261Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extensionIn: BMC Endocrine Disorders Jg. 21 (2021) Nr. 1, 161Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodelingIn: Journal of Nuclear Cardiology Jg. 28 (2021) Nr. 3, S. 812 - 821Online Volltext: dx.doi.org/ (Open Access)
-
Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancerIn: EJNMMI Physics Jg. 8 (2021) Nr. 1, 14Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapyIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 3, S. 002262Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including 18F-FDG PET/MRI, in Newly Diagnosed Breast Cancer : A Comparative Study Using Histopathology as the Reference StandardIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 12, S. 1677 - 1683Online Volltext: dx.doi.org/ (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: JAMA Oncology Jg. 7 (2021) Nr. 11, S. 1635 - 1642Online Volltext: dx.doi.org/ (Open Access)
-
Digital and respiratory-gated FDG PET/CT for characterization of lung lesionsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 83
-
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerIn: Nuclear Medicine and Biology Jg. 96-97 (2021) S. 101 - 111Online Volltext: dx.doi.org/ (Open Access)
-
Enzalutamide enhances psma expression of psma-low prostate cancerIn: International Journal of Molecular Sciences (IJMS) Jg. 22 (2021) Nr. 14, 7431Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Equivalent tumor detection for early and late FAPI-46 PET acquisitionIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 10, S. 3221 - 3227Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of [⁶⁸Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph visionIn: EJNMMI Research Jg. 11 (2021) Nr. 1, S. 21Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Evaluation of ¹⁸F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph visionIn: BMC Cancer Jg. 21 (2021) Nr. 1, 62Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trialIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 2, S. 501 - 508Online Volltext: dx.doi.org/ (Open Access)
-
Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 13, S. 4377 - 4385Online Volltext: dx.doi.org/ (Open Access)
-
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 5, S. 675 - 678Online Volltext: dx.doi.org/ (Open Access)
-
Imaging Inflammation with Positron Emission TomographyIn: Biomedicines Jg. 9 (2021) Nr. 2, S. 212Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Just another “Clever Hans”? : Neural networks and FDG PET-CT to predict the outcome of patients with breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 10, S. 3141 - 3150Online Volltext: dx.doi.org/ (Open Access)
-
Lung uptake detected by ⁶⁸Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2 : a case seriesIn: American Journal of Nuclear Medicine and Molecular Imaging Jg. 11 (2021) Nr. 4, S. 300 - 306Online Volltext (Open Access)
-
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 7, S. 989 - 995Online Volltext: dx.doi.org/ (Open Access)
-
N-staging in large cell neuroendocrine carcinoma of the lung : diagnostic value of [¹⁸F]FDG PET/CT compared to the histopathology reference standardIn: EJNMMI Research Jg. 11 (2021) Nr. 1, 68Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology Jg. 22 (2021) Nr. 8, S. 1115 - 1125Online Volltext: dx.doi.org/ (Open Access)
-
Oldies (but Goldies) : Die Peritonealszintigrafie bei PeritonealdialyseIn: Nuklearmedizin = Nuclear Medicine Jg. 60 (2021) Nr. 06, S. 450 - 453Online Volltext: dx.doi.org/
-
PET/CT versus PET/MRT bei Kopf-Hals-TumorenIn: TumorDiagnostik & Therapie Jg. 42 (2021) Nr. 5, S. 354 - 360Online Volltext: dx.doi.org/
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 4, S. 1200 - 1210Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 12, S. 1747 - 1750Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : study protocolIn: BMC Cancer Jg. 21 (2021) 512Online Volltext: dx.doi.org/ (Open Access)
-
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patientsIn: European Radiology Jg. 31 (2021) Nr. 11, S. 8714 - 8724Online Volltext: dx.doi.org/ (Open Access)
-
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC) : efficacy results of the UCLA cohortIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 10, S. 1440 - 1446Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging : Utilization of a short-pass filter to reduce technical pitfallsIn: Translational Andrology and Urology Jg. 10 (2021) Nr. 10, S. 3972 - 3985Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate CancerIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 279 - 287Online Volltext: dx.doi.org/
-
Prostate-specific membrane antigen PET in prostate cancerIn: Radiology Jg. 299 (2021) Nr. 2, S. 248 - 260Online Volltext: dx.doi.org/
-
Reply: The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 7, S. 1022Online Volltext: dx.doi.org/ (Open Access)
-
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617 : Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)In: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 10, S. 1447 - 1456Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124In: Scientific Reports Jg. 11 (2021) Nr. 1, 17477Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Theranostics in oncology : What radiologists want to knowIn: European Journal of Radiology Jg. 142 (2021) 109875Online Volltext: dx.doi.org/
-
Update from PSMA-SRT Trial NCT03582774 : A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical OutcomeIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 238 - 240Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Value of PET imaging for radiation therapyIn: Nuklearmedizin = Nuclear Medicine Jg. 60 (2021) Nr. 5, S. 326 - 343Online Volltext: dx.doi.org/ (Open Access)
-
Value of PET imaging for radiation therapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 179 (2021) Nr. 9, S. 757 - 779Online Volltext: dx.doi.org/ (Open Access)
-
Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PETIn: Clinical Nuclear Medicine Jg. 46 (2021) Nr. 10, S. 807 - 813Online Volltext: dx.doi.org/
-
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 2, S. 191 - 194Online Volltext: dx.doi.org/ (Open Access)
-
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase InhibitorsIn: Oncology Research and Treatment Jg. 44 (2021) Nr. 7-8, S. 400 - 407Online Volltext: dx.doi.org/ (Open Access)
-
[⁶⁸Ga]Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 9, S. 1235 - 1241Online Volltext: dx.doi.org/ (Open Access)
-
Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [¹⁸F]FDG PET/CT and [¹⁸F]FDG PET/MRIIn: Nuclear Medicine and Molecular Imaging Jg. 54 (2020) Nr. 4, S. 183 - 191Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy : An ¹²³I-metaiodobenzylguanidine SPECT/CT studyIn: Journal of Nuclear Cardiology Jg. 27 (2020) Nr. 6, S. 2402 - 2409Online Volltext: dx.doi.org/ (Open Access)
-
Can the injected dose be reduced in ⁶⁸Ga-PSMA-11 PET/CT while maintaining high image quality for lesion detection?In: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 2, S. 189 - 193Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and Safety of ¹⁷⁷Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement : A Multicenter Retrospective StudyIn: European Urology Jg. 78 (2020) Nr. 2, S. 148 - 154Online Volltext: dx.doi.org/
-
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using ⁶⁸Ga-PSMA-11In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. 13, S. 3194 - 3195Online Volltext: dx.doi.org/
-
Imaging inflammation after myocardial infarction : implications for prognosis and therapeutic guidanceIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 64 (2020) Nr. 1, S. 35 - 50Online Volltext: dx.doi.org/
-
Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings : A Prospective Single-Center StudyIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 8, S. 1153 - 1160Online Volltext: dx.doi.org/ (Open Access)
-
In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CTIn: Acta Biomaterialia Jg. 109 (2020) S. 244 - 253Online Volltext: dx.doi.org/
-
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PETIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 7, S. 1037 - 1042Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Neuroendokrine Neoplasien des VerdauungstraktsIn: Best Practice Onkologie Jg. 15 (2020) Nr. 7-8, S. 320 - 333Online Volltext: dx.doi.org/
-
Outcome after 68ga-psma-11 versus choline pet-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer : A matched-pair analysisIn: Cancers Jg. 12 (2020) Nr. 11, S. 3395Online Volltext: dx.doi.org/ (Open Access)
-
Prospective evaluation of whole-body MRI and ¹⁸F-FDG PET/MRI in N and M staging of primary breast cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. 12, S. 2816 - 2825Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrenceIn: Current Opinion in Urology Jg. 30 (2020) Nr. 5, S. 635 - 640Online Volltext: dx.doi.org/
-
Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumorsIn: Nuclear Medicine Communications Jg. 41 (2020) Nr. 4, S. 363 - 369Online Volltext: dx.doi.org/
-
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from ⁶⁸Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficientIn: BMC Cancer Jg. 20 (2020) Nr. 1, 326Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Whole-Body Integrated [⁶⁸Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer : Comparison with Whole-Body PET/CT as the Standard of ReferenceIn: Molecular Imaging and Biology Jg. 22 (2020) Nr. 3, S. 788 - 796Online Volltext: dx.doi.org/
-
¹⁸F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitisIn: PLoS ONE Jg. 15 (2020) Nr. 1, S. e0227906Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue SarcomasIn: Journal of Nuclear Medicine (JNM) Jg. 60 (2019) Nr. 11, S. 1537 - 1542Online Volltext: dx.doi.org/ (Open Access)
-
Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer : A Prospective Single-Arm Clinical TrialIn: JAMA Oncology Jg. 5 (2019) Nr. 6, S. 856 - 863Online Volltext: dx.doi.org/ (Open Access)
-
EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT)In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 46 (2019) Nr. 12, S. 2536 - 2544Online Volltext: dx.doi.org/
-
Improving ⁶⁸Ga-PSMA PET/MRI of the prostate with unrenormalized absolute scatter correctionIn: Journal of Nuclear Medicine (JNM) Jg. 60 (2019) Nr. 11, S. 1642 - 1648Online Volltext: dx.doi.org/ (Open Access)
-
Meta-analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by HistopathologyIn: Journal of Nuclear Medicine (JNM) Jg. 60 (2019) Nr. 6, S. 786 - 793Online Volltext: dx.doi.org/ (Open Access)
-
Molecular Imaging for Primary Staging of Prostate CancerIn: Seminars in Nuclear Medicine Jg. 49 (2019) Nr. 4, S. 271 - 279Online Volltext: dx.doi.org/
-
Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy : A 2-institution retrospective analysisIn: Journal of Nuclear Medicine (JNM) Jg. 60 (2019) Nr. 2, S. 227 - 233Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research Jg. 25 (2019) Nr. 24, S. 7448 - 7454Online Volltext: dx.doi.org/ (Open Access)
-
Salvage PRRT with ¹⁷⁷Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET) : Dosimetry, toxicity, efficacy, and survivalIn: BMC Cancer Jg. 19 (2019) Nr. 1, S. 788Online Volltext: dx.doi.org/ (Open Access)
-
Theranostics for Advanced Prostate Cancer : Current Indications and Future DevelopmentsIn: European Urology Oncology Jg. 2 (2019) Nr. 2, S. 152 - 162Online Volltext: dx.doi.org/
-
Theranostik von soliden Tumoren : Renaissance eines alten KonzeptsIn: Best Practice Onkologie Jg. 14 (2019) Nr. 12, S. 526 - 534Online Volltext: dx.doi.org/
-
What is the best PET target for early biochemical recurrence of prostate cancer? : Authors’ replyIn: The Lancet Oncology Jg. 20 (2019) Nr. 11, S. e609 - e610Online Volltext: dx.doi.org/
-
¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy : a prospective, single-centre, single-arm, comparative imaging trialIn: The Lancet Oncology Jg. 20 (2019) Nr. 9, S. 1286 - 1294Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrenceIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 5, S. 789 - 794Online Volltext: dx.doi.org/ (Open Access)
-
Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 9, S. 1392 - 1397Online Volltext: dx.doi.org/ (Open Access)
-
Ergebnisse der LuPSMA-Studie zeigen hohe Ansprechraten mit geringer Toxizität und SchmerzlinderungIn: Der Urologe Jg. 57 (2018) Nr. 12, S. 1494 - 1495Online Volltext: dx.doi.org/
-
Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI : Current and future applicationsIn: American Journal of Roentgenology (AJR online) Jg. 211 (2018) Nr. 2, S. 286 - 294Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Potential impact of ⁶⁸Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancerIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 11, S. 1714 - 1721Online Volltext: dx.doi.org/ (Open Access)
-
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancerIn: EJNMMI Research Jg. 8 (2018) Nr. 1, 96Online Volltext: dx.doi.org/ (Open Access)
-
Prostate cancer molecular imaging standardized evaluation (PROMISE) : Proposed miTNM classification for the interpretation of PSMA-ligand PET/CTIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 3, S. 469 - 478Online Volltext: dx.doi.org/ (Open Access)
-
⁶⁸Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL : Impact on salvage radiotherapy planningIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 2, S. 230 - 237Online Volltext: dx.doi.org/ (Open Access)
-
177Lu-PSMA Radioligand Therapy for Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 58 (2017) Nr. 8, S. 1196 - 1200Online Volltext: dx.doi.org/ (Open Access)
-
A PET for All Seasons : 18F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?In: European Urology Jg. 71 (2017) Nr. 6, S. 934 - 935Online Volltext: dx.doi.org/
-
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerIn: Journal of Nuclear Medicine (JNM) Jg. 58 (2017) Nr. 11, S. 1786 - 1792Online Volltext: dx.doi.org/ (Open Access)
-
PSMA ligands in prostate cancer – Probe optimization and theranostic applicationsIn: Methods: A Companion to Methods in Enzymology Jg. 130 (2017) S. 42 - 50Online Volltext: dx.doi.org/
-
Prostate-specific membrane antigen ligands for imaging and therapyIn: Journal of Nuclear Medicine (JNM) Jg. 58 (2017) Nr. Suppl. 2, S. 67S - 76SOnline Volltext: dx.doi.org/
-
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit : A Roadmap for Research and Clinical Application in Nonmetastatic Prostate CancerIn: European Urology Jg. 86 (2024) Nr. 2, S. 81 - 87Online Volltext: dx.doi.org/
-
May the Nuclear Medicine be with you! : Neuroendocrine tumours and the return of nuclear medicineIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 25 (2024) Nr. 1, S. 3 - 8Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker : Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate CancerIn: European Urology (2024) in pressOnline Volltext: dx.doi.org/
-
The novel PROMISE framework for PSMA-PET reporting : Ready for the clinical routine?In: Clinical and Translational Imaging Jg. 12 (2024) Nr. 1, S. 1 - 3Online Volltext: dx.doi.org/ (Open Access)
-
2021: the year [¹⁷⁷Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo GerickeIn: European Journal of Nuclear Medicine and Molecular Imaging (2021)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Nuclear Medicine Beyond VISIONIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 7, S. 916 - 917Online Volltext: dx.doi.org/ (Open Access)
-
We Can Make a Difference : Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate CancerIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 227 - 228Online Volltext: dx.doi.org/
-
Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancerIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 5016Online Volltext: dx.doi.org/
-
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S415Online Volltext: dx.doi.org/ (Open Access) -
68Ga-FAPI-46 PET for imaging of FAP expressing cancer - interim findings from a single-center prospective interventional single-arm clinical trialIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P706
-
68Ga-NeoB PET for Glioma and Breast Cancer : First Results from a Prospective Observational Trial
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S265Online Volltext: dx.doi.org/ (Open Access) -
68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer PatientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. 488 - S489Online Volltext: dx.doi.org/
-
68Ga-Satoreotide PET for Staging of Small-Cell Lung Cancer PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P165
-
A retrospective multicenter analysis of the incidence of bone only disease at PSMA PET/CT in Castration Resistant Prostate Cancer (CRPC) patients
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P299 -
Analysing the Tumour Transcriptome of Prostate Cancer to Predict Efficacy of Lu-PSMA Therapy
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S180Online Volltext: dx.doi.org/ (Open Access) -
Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? : External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1, S. S923 - S924Online Volltext: dx.doi.org/ -
Do Bone Scans Over Stage Disease Compared to PSMA PET? : An international multicenter retrospective study with blinded independent readers
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P1094 -
Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P714
-
From CHAARTED low- and high-volume disease to PSMA PET imaging volume in mHSPC patients : an international multicenter retrospective study
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S230 - S231Online Volltext: dx.doi.org/ (Open Access) -
Head-to-head comparison of68Ga-FAPI46 PET/CT,18F-FDG PET/CT, and contrast- enhanced CT in patient with various solid tumors
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. 166 - S167Online Volltext: dx.doi.org/ (Open Access) -
Identifying the optimal candidates for a super-extended staging pelvic lymph-node dissection in prostate cancer patients treated in the PET-PSMA era. : Results from a multi-institutional series
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1, S. S925 - S926Online Volltext: dx.doi.org/ -
Improving prediction of local stage by PSMA-PET : Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer
38th Annual European Association of Urology (EAU) Congress ; March 10 - 13, 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1: Abstracts EAU23, S. S1778 - S1779Online Volltext: dx.doi.org/ -
Improving radical prostatectomy with intraoperative ex-vivo PSMA-PET/CT imaging
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S586Online Volltext: dx.doi.org/ (Open Access) -
Inter-institutional differences and common ground in 177Lu-PSMA radionuclide therapy : International survey in 95 theranostic centers
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P843 -
Inter-institutional differences and common ground in 177Lu-PSMA radionuclide therapy : International survey in 95 theranostic centersIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. Suppl. 1, S. S92Online Volltext: dx.doi.org/ (Open Access)
-
Intraoperative microPET/CT imaging for PSMA-positive cancer foci in radical prostatectomy – feasibility study
38th Annual EAU (European Association of Urology) Congress ; EAU23 ; 10 - 13 March 2023, Milan, Italy,In: European Urology Jg. 83 (2023) Nr. Supplement 1, S. S687Online Volltext: dx.doi.org/ -
Performance Evaluation of 18F-PSMA and 68Ga-PSMA in a Novel MicroPET/CT System Dedicated to Radioguided Surgery
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S131Online Volltext: dx.doi.org/ (Open Access) -
Practical RECIP : Visual assessment of Response Evaluation Criteria In PSMA-PET/CT in metastatic castration-resistant prostate cancer
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P1619 -
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of Pelvic Lymph Node Dissection? : Follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P440 -
Prognostic value of the post-treatment 177Lu-DOTATOC scintigraphy in NET patients undergoing PRRT
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S134Online Volltext: dx.doi.org/ (Open Access) -
Prostate Cancer Molecular Imaging Standardized Evaluation : The PROMISE V2 Framework Including Response Evaluation for Clinical TrialsIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S150Online Volltext: dx.doi.org/ (Open Access)
-
Safety and Efficacy of Extended 177Lu-PSMA Therapy: Multi-Center Retrospective Analysis
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S152Online Volltext: dx.doi.org/ (Open Access) -
Safety and effectiveness of Lutetium-177–Prostate-Specific Membrane Antigen in patients with metastatic castration-resistant prostate cancer with and without visceral metastases who had received prior radium-223 : A post hoc analysis of the RALU study
55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON); NOV 16-19, 2023; Jodhpur, India,In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P607 -
The Updated Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE V2.0) Framework for Standardized Reporting of PSMA-PET
Annual Congress of the European Association of Nuclear Medicine, 19-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S177Online Volltext: dx.doi.org/ (Open Access) -
Therapiepause nach 2 Jahren Immuntherapie bei einer metabolischen Komplettremission beim NSCLC
63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.,In: Pneumologie Jg. 77 (2023) Nr. S 01, S. S46Online Volltext: dx.doi.org/ -
Updated Automated PROMISE assessment : Treatment response evaluation approach on metastatic prostate cancer patients based on PSMA PET/CT
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S18Online Volltext: dx.doi.org/ (Open Access) -
68GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S107Online Volltext: dx.doi.org/ (Open Access) -
Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S80Online Volltext: dx.doi.org/ (Open Access) -
FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) : a triple tracer comparison
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S118 - S119Online Volltext: dx.doi.org/ (Open Access) -
Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management : Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774]In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 5028Online Volltext: dx.doi.org/
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S267Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S269Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : An international multicenter study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S794 - S795Online Volltext: dx.doi.org/ -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
2022 ASCO Genitourinary Cancers Symposium, 17.-19.02.2022, San Fransisco,In: Journal of Nuclear Medicine (JNM) Jg. 40 (2022) Nr. 6, Supplement: 2022 ASCO Genitourinary Cancers Symposium, jnumed.121.263072Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. Suppl. 6, 42Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PSMA PET disease extent for European Association of Urology biochemical recurrence risk groups : An international multicentre study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S291Online Volltext: dx.doi.org/ -
PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy : An international multicenter retrospective studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 5043Online Volltext: dx.doi.org/ (Open Access)
-
PSMA-directed imaging and therapy of salivary gland tumors : a single-center retrospective study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S229Online Volltext: dx.doi.org/ (Open Access) -
Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET : An international multicenter retrospective studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. Suppl. 6, 32Online Volltext: dx.doi.org/ (Open Access)
-
Radiation Exposure of I-124-MIBG Imaging in Adult Patients with Neuroendocrine Tumours
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S36 - S37Online Volltext: dx.doi.org/ (Open Access) -
Re: Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: The Journal of Urology Jg. 207 (2022) Nr. 4, S. 930Online Volltext: dx.doi.org/
-
Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra) : The RALU Study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S54 - S55Online Volltext: dx.doi.org/ (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 - S1232Online Volltext: dx.doi.org/ (Open Access) -
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra) : Interim analysis of the RALU studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 5040 - 5040Online Volltext: dx.doi.org/
-
Superiority of [68Ga]Ga-FAPI-46 over [18F]F-FDG PET/CT for cholangiocarcinoma imaging
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S192 - S193Online Volltext: dx.doi.org/ (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S119 - S120Online Volltext: dx.doi.org/ (Open Access) -
VISION read criteria of 68Ga-PSMA-11 PET scans for patient eligibility to 177Lu-PSMA-617 therapy : a simple and reproducible methodology
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S129 - S130Online Volltext: dx.doi.org/ (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76
-
Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9050 - 9050Online Volltext: dx.doi.org/
-
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter study
EANM‘21 ; 34th Annual Congress of the European Association of Nuclear Medicine ; October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. S311 - S312Online Volltext: dx.doi.org/ (Open Access) -
Dynamic Ga-68-DOTA PET/CT and Compartmental Modelling to Non-invasively Estimate the Glomerular Filtration RateIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. Suppl. 1, 88
-
Efficacy and safety of 124-I-MIBG guided high activity 131-I-MIBG therapy of metastatic pheochromocytoma and neuroblastomaIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 290 - S291
-
Evaluation of Dynamic Renal Ga-68-DOTA PET/CT to Monitor the Urinary Efflux and to Estimate the Glomerular Filtration Rate Using a Compartmental Kinetic Modelling ApproachIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 340
-
FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinoma
2021 ASCO Annual Meeting, 4. - 8. June 2021, virtuell,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. Suppl. 15, S. e16564Online Volltext: dx.doi.org/ (Open Access) -
Ga-68-FAPI for sarcoma imaging : Data from the FAPI-PET prospective observational trialIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. Suppl. 1, 126
-
Ga-68-versus F-18-PSMA for Cerenkov Luminescence and autoradiography in a prostate cancer mouse modelIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 17
-
Imaging Properties and Quantification Accuracy of Ga-68 and I-124 in a New Generation Preclinical PET/CT System : A Phantom StudyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 227 - S228
-
Impact of PSMA PET/CT on SRT planning : Preliminary results from the randomized phase III trial NCT03582774
2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 6, Supplement, S. 30 - 30Online Volltext: dx.doi.org/ (Open Access) -
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumors
Annual Congress of the European Association of Nuclear Medicine, October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. S290Online Volltext: dx.doi.org/ -
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET) : An explorative, multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 5066 - 5066Online Volltext: dx.doi.org/
-
Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer : An international multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 63 - S64
-
PSMA PET and radiomics for the evaluation of liver metastases in castration-resistant prostate cancer patients : A multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 234
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study ProtocolIn: Cancer Research Jg. 81 (2021) Nr. 13, CT257
-
Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study protocol NCT04457245
2021 Genitourinary Cancers Symposium, 11 - 13 Feb 2021, online,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 6, Supplement, S. TPS172Online Volltext: dx.doi.org/ (Open Access) -
Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI-PETIn: European Heart Journal Jg. 42 (2021) Nr. Supplement_1, ehab724.0255Online Volltext: dx.doi.org/ (Open Access)
-
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection : A multicenter prospective phase III imaging study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S209Online Volltext: dx.doi.org/ (Open Access) -
Comparison of Lesion Detectability and Image Quality among Digital and Analog PET Systems for Recurrence in Thyroid Cancer Patients Using I-124
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S429Online Volltext: dx.doi.org/ (Open Access) -
Effects of anti-TNF-therapy on osteoblastic activity in ankylosing spondylitis : Results from a prospective study using PET-MRI of SIJ and SPINE
EULAR: Annual European Congress of Rheumatology, 2020, 03.-06.06.2020, Frankfurt,In: Annals of the Rheumatic Diseases (ARD) Jg. 79 (2020) Nr. Suppl. 1, S. 1125 - 1126Online Volltext: dx.doi.org/ (Open Access) -
Impact of PSMA PET/CT on SRT planning: Preliminary results from a randomized phaseIII trial
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. 22Online Volltext: dx.doi.org/ (Open Access) -
Lymphonodular anthracosis in patients undergoing FDG PET/CT for initial lung cancer diagnostics and/or staging is a mayor pitfall : a comparison to the histological gold standard
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S565 - S566Online Volltext: dx.doi.org/ (Open Access) -
Overall survival after177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer : Post-hoc analysis of a prospective phase II trial
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S488Online Volltext: dx.doi.org/ (Open Access) -
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S487Online Volltext: dx.doi.org/ (Open Access) -
Salvage therapies for PSMA PET-positive nodal recurrent prostate cancerIn: Radiotherapy and Oncology (The Green Journal) Jg. 152 (2020) Nr. Supplement 1, S. 614Online Volltext: dx.doi.org/
-
Low- and high-volume disease in mHSPC : From CHAARTED to PSMA PET
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S967Online Volltext: dx.doi.org/ -
Comparison of the Safety and Tolerability of Paraaminohippurate (PAH) and Amino Acid (AA) Co-Infusion in Patients with Neuroendocrine Tumours Receiving Peptide Receptor Radionuclide Therapy (PRRT) : A Case Series of Eight Patients
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S579Online Volltext: dx.doi.org/ (Open Access) -
Immuntherapie eines Mikrosatelliten-instabilen metastasierten Talgdrüsenkarzinoms der Glandula submandibularis mit Pembrolizumab
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 230 - 231Online Volltext: dx.doi.org/ (Open Access) -
Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S636Online Volltext: dx.doi.org/ (Open Access) -
Metastasenfreies Überleben und Fernmetastasen-Muster nach PSMA-PET-gesteuerter Salvage-Radiotherapie bei rezidivierendem oder persistierendem Prostatakarzinom nach Prostatektomie
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. Supplement 1, S. S117Online Volltext: dx.doi.org/ (Open Access)